Ipsen – Consolidated Financial Statements – 2022

- 16 February 2023 - 0 mins read
Related stories
14 October 2024 0 mins read

Excellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes
29 June 2022 0 mins read

Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission
01 June 2021 0 mins read

Ipsen announces the launch of an Employee Shareholding Plan
See more stories

Related Press Releases

11 July 2024

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
09 July 2024

IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
09 July 2024

Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share...
08 July 2024

Half-year statement of IPSEN liquidity agreement – 2024 06 30
02 July 2024

IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
02 July 2024

Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III...
25 June 2024

IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
18 June 2024

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
11 June 2024

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
10 June 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis